The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,196,886 in first-year total cost, median $199,866.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IDM-U (10)]1
- Special Emphasis Panel[ZRG1 IMM-N (12)]1
- Special Emphasis Panel[ZRG1 MOSS-T (12)]1
- Special Emphasis Panel[ZRG1 OTC-H (13)]1
- Special Emphasis Panel[ZRG1 SBIB-V (12)]1
Most frequent institutions
- AFFINITY THERAPEUTICS, LLC1
- CODAGENIX, INC.1
- MARROWSOURCE THERAPEUTICS INTERNATIONAL1
- ONCOIMMUNE, INC.1
- SCARLESS LABORATORIES, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Affinity-based delivery of Sirolimus for prevention of AV graft failure1R43HL121928-01A1 | ZUCKERMAN, SEAN T. | AFFINITY THERAPEUTICS, LLC, OH | $199,999 | ZRG1 |
| 2014 | Targeting endogenous sialidases for treatment of endotoxic shock1R43AI108115-01A1 | QIU, PING | ONCOIMMUNE, INC., MD | $199,956 | ZRG1 |
| 2014 | Ultra-low dose Influenza vaccines1R43AI109924-01 | MUELLER, STEFFEN | CODAGENIX, INC., NY | $199,904 | ZRG1 |
| 2014 | Enhancing engraftment of cord blood for treatment of neoplastic disorders1R43HL122000-01A1 | JIANG, XUN | MARROWSOURCE THERAPEUTICS INTERNATIONAL, NY | $199,827 | ZRG1 |
| 2014 | Safety and efficacy testing of novel anti-scar peptide vs corticosteroid for scar1R43AR063558-01A1 | PANG, SHENSOO, CHIA | SCARLESS LABORATORIES, INC., CA | $198,944 | ZRG1 |
| 2014 | Development of the VirtualTAVR system for diagnostics and preventative strategies1R43HL124798-01 | PHAM, THUY MPRIMIANO, CHARLES | SUTRA MEDICAL, INC., CA | $198,256 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.